Floatz logo

PEGASPARGASE

B Acute Lymphoblastic Leukemia, BCR-ABL1-Like

Children's Oncology Groupprotein_peptidePhase 3Active
B
63/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
54/ 100
Competitive Position
81/ 100

Competitive context

34 Active assets in the B Acute Lymphoblastic Leukemia, BCR-ABL1-Like cohort.

Asset / SponsorPhaseRating
Nilotinib
The University of Hong Kong
Phase 2BBB
Blinatumomab
Novartis Pharmaceuticals
Phase 3BBB
Cytosin-Arabinosid
Novartis Pharmaceuticals
Phase 3BBB
METHOTREXATE
Novartis Pharmaceuticals
Phase 3BB
Imatinib
The University of Hong Kong
Phase 3BB

View all 50 →

Same molecule, other indications

PEGASPARGASE is also rated in:

B-cell childhood acute lymphoblastic leukemiaDormant
A
Indicative ·
80 / 100
View asset →
Adult Acute Lymphocytic LeukemiaDormant
BBB
Indicative ·
77 / 100
View asset →
extranodal nasal NK/T cell lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →